However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been unchanged by 0%, while EPS estimates have been unchanged by 0%. For the upcoming Q4 2025, revenue estimates have been adjusted revised downward by -0.87%. These revisions correlate with a -12.72% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in BIO long-term fundamentals.

The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

RevenueEPS

Currency: USD

Revenue Estimate-:0

EPS Estimate-:0

—

Stock Price0

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Revenue Estimates for Q4 2025

Revise Downward

-0.87%

In Past 3 Month

Stock Price

Go Down

-12.72%

In Past 3 Month

Earnings Forecast

Revenue

EPS

Currency: USD

Actual

Estimate

AI Analysis

Earnings Surprise Analysis

Revenue

EPS

AI Analysis

Earnings Reaction

The chart below shows how BIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BIO sees a 2.76% change in stock price 10 days leading up to the earnings, and a 1.91% change 10 days following the report. On the earnings day itself, the stock moves by -0.99%. This data can give you a slight idea of what to expect for the next quarter's release.

For example, in DEC/2025, the stock changed -12.26% on the day following the earnings release and then changed by -4.78% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.

People Also Watch

Frequently Asked Questions

What were the key highlights of BIO's latest earnings report for ?

BIO reported its earnings on 2026-02-12, showcasing a revenue of 693.20M against an estimate of 693.11M, resulting in a 0.01% surprise. The EPS was 2.51, surpassing the expected 2.57 by -2.33%. The stock experienced a -12.26% price change on the earnings day and a -7.02% change over the next five days, reflecting market reactions to the results.

How did BIO's stock price react after the earnings release?

Following BIO's earnings announcement on 2026-02-12, the stock price moved by -12.26% on the day of the release. Over the subsequent five days, it saw a -7.02% change. Historically, BIO's stock price tends to shift by an average of 2.76% in the 10 days leading up to earnings and 1.91% in the 10 days following, providing insight into potential market.

What are the revenue and EPS estimates for BIO for 2026/Q1?

For 2026/Q1, analysts estimate BIO's annual revenue to reach 601.86M, while the EPS is projected at 2.54. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -0.87% over the past three months, indicating analyst expectation in the company's performance.

How does BIO's stock price correlate with earnings forecast revisions?

The correlation between BIO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -0.87%. This trend suggests that price dips could present buying opportunities for investors.

What should investors expect from BIO's next earnings report?

Based on historical trends, BIO's stock price typically moves by 2.76% in the 10 days before its earnings and 1.91% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 2.54 and revenue of 601.86M.

What is the sentiment in Bio Rad Laboratories Inc (BIO) Q4 2025 Earnings Call Summary?

The earnings call presents a mixed picture: modest revenue growth in diagnostics and improved free cash flow contrast with declining margins and net income. The Q&A reveals cautious management guidance and uncertainties in process chromatography. Despite strong growth in ddPCR and cash reserves, the lack of buyback and management's vague responses temper optimism. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.

BIO Earnings

BIO Earnings

Quarterly Results

BIO Earnings Forecast

Earnings Forecast

Earnings Surprise Analysis

People Also Watch

Frequently Asked Questions

What were the key highlights of BIO's latest earnings report for ?

How did BIO's stock price react after the earnings release?

What are the revenue and EPS estimates for BIO for 2026/Q1?

How does BIO's stock price correlate with earnings forecast revisions?

What should investors expect from BIO's next earnings report?

What is the sentiment in Bio Rad Laboratories Inc (BIO) Q4 2025 Earnings Call Summary?